Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY [0.03%]
德雷斯顿NOAC登记处关于依度沙班在重大手术或操作中管理的研究结果
Christina Köhler,Luise Tittl,Ulrike Hänsel et al.
Christina Köhler et al.
Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism (VTE) treatment or stroke prevention in atrial fibrillation. Major surgical procedures are not uncommon in anticoagulated patient...
Surgery As a Trigger for Incident Venous Thromboembolism: Results from a Population-Based Case-Crossover Study [0.03%]
基于人群的病例交叉研究中手术作为静脉血栓栓塞症的诱发因素的研究结果
Dana Meknas,Sigrid K Brækkan,John-Bjarne Hansen et al.
Dana Meknas et al.
Background Surgery is a major transient risk factor for venous thromboembolism (VTE). However, the impact of major surgery as a VTE trigger has been scarcely investigated using a case-crossover design. Aim To investigate the role of major s...
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan [0.03%]
日本艾美赛珠单抗临床研究标本库中抗艾美赛珠单抗抗体的特征分析
Naoki Matsumoto,Hiroto Abe,Ryohei Kawasaki et al.
Naoki Matsumoto et al.
Judith J de Vries,Chantal Visser,Maureen van Ommen et al.
Judith J de Vries et al.
Background Fibrinogen variants as a result of alternative messenger RNA splicing or protein degradation can affect fibrin(ogen) functions. The levels of these variants might be altered during coronavirus disease 2019 (COVID-19), potentially...
Kashyap Patel,Omaike Sikder,Nikhil Nair et al.
Kashyap Patel et al.
Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale [0.03%]
PCC对FXa抑制剂相关大出血或需紧急手术患者血栓形成影响的前瞻性研究(GAUGE)：设计与理由
Joseph R Shaw,Ubabuko Unachukwu,Joseph Cyr et al.
Joseph R Shaw et al.
Background Direct factor Xa inhibitors (FXaIs) account for most oral anticoagulant use and FXaI-associated bleeding events are common. Clinicians have variable national and regional access to specific FXaI reversal agents such as andexanet ...
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding [0.03%]
低出血风险肿瘤相关静脉血栓栓塞症患者的利伐沙班和阿哌沙班的对比研究
Kimberly Snow Caroti,Cecilia Becattini,Marc Carrier et al.
Kimberly Snow Caroti et al.
This retrospective study, utilizing U.S. electronic health record (EHR) data from January 2013 to December 2020, sought to assess whether rivaroxaban and apixaban had similar effectiveness and safety in the treatment of cancer-associated ve...
A Combination of Ex Vivo and In Vivo Strategies for Evaluating How Much New Oral Anticoagulants Exacerbate Experimental Intracerebral Bleeding [0.03%]
体外和体内策略的结合评估新型口服抗凝药物加重实验性脑内出血的潜力
Juliana R P Ferreira,Isabela D Sucupira,Gabriella M C Carvalho et al.
Juliana R P Ferreira et al.
Background Intracerebral hemorrhage is the most serious complication of anticoagulant therapy but the effects of different types of oral anticoagulants on the expansion of these hemorrhages are still unclear. Clinical studies have revealed ...
The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome [0.03%]
利妥昔单抗对抗磷脂综合征患者抗磷脂滴度的影响
Kimberley Youkhana,Hilary Heiling,Allison Deal et al.
Kimberley Youkhana et al.
Potential for a Virtual Care Model in the Perioperative Management of Anticoagulant Therapy: A 5-Year Retrospective Clinic Review [0.03%]
围手术期抗凝治疗管理虚拟医疗模式的应用前景：5年门诊回顾分析
James Luke Douketis,Sam Schulman
James Luke Douketis
Background With a trend toward greater virtual care in selected clinical settings, perioperative anticoagulant management appears well suited for this care delivery model. We explored the potential for virtual care among patients who are re...